公开(公告)号：US20200052222A1

公开(公告)日：2020-02-13

申请号：US16531584

申请日：2019-08-05

Applicant: LG Display Co., Ltd.

Inventor： Suk-Young Bae ,  In-Ae Shin ,  Jun-Yun Kim

IPC: H01L51/00 ,  C07D233/58 ,  C09K11/06 ,  C07D277/22 ,  C07D209/88

Abstract: An organic compound having a spiro-anthracene core and an aromatic or heteroaromatic group and/or an amino group bonded to the core, and an organic light-emitting diode and an organic light-emitting device including the organic compound are disclosed. Since the organic compound of the present disclosure has a rigid structure and a substantially narrow full width at half maximum (FWHM), it is possible to manufacture an organic light-emitting diode and an organic light-emitting device with lowered driving voltages and enhanced luminous efficiency and color purity using the organic compound.

公开(公告)号：US20200020860A1

公开(公告)日：2020-01-16

申请号：US16483986

申请日：2018-02-05

Applicant: NISSAN CHEMICAL CORPORATION

Inventor： Naoki NAKAIE ,  Daisuke MAEDA

IPC: H01L51/00 ,  C09D5/24 ,  C07C381/12 ,  C07F5/02 ,  C07D209/88

Abstract: Provided is a charge transporting varnish comprising: a charge transporting substance such as an aniline derivative and a thiophene derivative; an onium borate salt such as a compound represented by the formula; and an organic solvent.

公开(公告)号：US20200004146A1

公开(公告)日：2020-01-02

申请号：US16563980

申请日：2019-09-09

Applicant: BASF SE

Inventor： Yuichi NISHIMAE ,  Hisatoshi KURA ,  Kazuhiko KUNIMOTO ,  Ryuhei YAMAGAMI ,  Keita TANAKA

IPC: G03F7/027 ,  G03F7/00 ,  C07D209/88 ,  G03F7/031 ,  G03F7/20 ,  G03F7/30 ,  C07D209/86 ,  C08F122/20 ,  C09D135/02 ,  G02B5/20 ,  G03F7/033 ,  G03F7/26

Abstract: Oxime ester compounds of the formula I, II, III, IV or V wherein Z is for example Z1 for is NO2, unsubstituted or substituted C7-C20aroyl or unsubstituted or substituted C4-C20heteroaroyl; provided that at least one Z1 is other than NO2; Z2 is for example unsubstituted or substituted C7-C20aroyl; R1, R2, R3, R4, R5 and R6 for example are hydrogen, halogen, or unsubstituted or substituted C1-C20alkyl, unsubstituted or substituted C6-C20aryl, or unsubstituted or substituted C4-C20heteroaryl; R9, R10, R11, R12 and R13 for example are hydrogen, halogen, OR16, unsubstituted or substituted C1-C20alkyl; provided that R9 and R13 are neither hydrogen nor fluorine; R14 is for example unsubstituted or substituted C6-C20aryl or C3-C20heteroaryl Q is for example C6-C20arylene or C3-C20heteroarylene; Q1 is —C1-C20alkylene-CO—; Q2 is naphthoylene; Q3 is for example phenylene; L is for example O-alkylene-O—; R15 is for example hydrogen or C1-C20alkyl; R20 is for example hydrogen, or unsubstituted or substituted C1-C20alkyl; are effective photoinitiators.

公开(公告)号：US10428095B2

公开(公告)日：2019-10-01

申请号：US16148622

申请日：2018-10-01

Applicant: Achillion Pharmaceuticals, Inc.

Inventor： Jason Allan Wiles ,  Avinash S. Phadke ,  Xiangzhu Wang ,  Dawei Chen ,  Akihiro Hashimoto ,  Venkat Rao Gadhachanda ,  Godwin Pais ,  Qiuping Wang ,  Atul Agarwal ,  Milind Deshpande

IPC: C07D403/14 ,  C07F9/572 ,  C07D209/42 ,  C07D403/12 ,  C07D401/14 ,  C07D471/04 ,  C07D417/06 ,  C07D403/06 ,  C07D417/14 ,  C07F7/08 ,  C07D413/14 ,  C07D487/04 ,  C07D405/14 ,  C07D403/08 ,  C07D413/06 ,  C07F5/02 ,  C07F9/6561 ,  C07F9/6558 ,  A61K31/404 ,  A61K31/407 ,  A61K31/4162 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4188 ,  A61K31/4192 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/549 ,  A61K31/55 ,  A61K31/675 ,  A61K31/683 ,  C07B59/00 ,  C07D209/14 ,  C07D209/40 ,  C07D405/12 ,  C07D417/12 ,  C07D487/14 ,  C07D491/113 ,  C07D495/04 ,  C07D513/04 ,  A61K9/00 ,  A61K31/4045 ,  A61K31/444 ,  A61K31/501 ,  A61K31/519 ,  C07D209/12 ,  C07D209/30 ,  C07D209/44 ,  C07D209/88 ,  C07D471/08

Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

公开(公告)号：US10421696B2

公开(公告)日：2019-09-24

申请号：US14972475

申请日：2015-12-17

Applicant: California Institute of Technology

Inventor： Brian M. Stoltz ,  Yoshitaka Numajiri ,  Beau P. Pritchett ,  Koji Chiyoda

IPC: C07B53/00 ,  C07D209/88 ,  C07D211/74 ,  C07D211/76 ,  C07D265/32 ,  C07C271/18 ,  C07C271/50 ,  C07C311/16 ,  C07C233/76

Abstract: This invention provides enantioenriched Mannich adducts with quaternary stereogenic centers and novel methods of preparing the compounds. Methods include the method for the preparation of a compound of formula (I): comprising treating a compound of formula (II): with a transition metal catalyst under alkylation conditions.

公开(公告)号：US10329254B2

公开(公告)日：2019-06-25

申请号：US15134028

申请日：2016-04-20

Applicant: AOP ORPHAN PHARMACEUTICALS AG

Inventor： Enrica Diodato ,  Katia Marcucci ,  Russell Thomas ,  Paul Wiedenau ,  Martin Rettig ,  Huw Roberts

IPC: C07D209/88

Abstract: The invention relates to a novel process for the preparation of rac-6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide (I) in pharmaceutically acceptable polymorphic form, through the conversion of a 3-bromo-2-oxo-cyclohexanecarboxylic acid alkyl ester into 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxylic acid alkyl ester, which in turn is processed to yield the final product.

公开(公告)号：US20190185498A1

公开(公告)日：2019-06-20

申请号：US16276139

申请日：2019-02-14

Applicant: Achillion Pharmaceuticals, Inc.

Inventor： Jason Allan Wiles ,  Venkat Rao Gadhachanda ,  Qiuping Wang ,  Godwin Pais ,  Akihiro Hashimoto ,  Dawei Chen ,  Xiangzhu Wang ,  Atul Agarwal ,  Milind Deshpande ,  Avinash S. Phadke

IPC: A61K31/683 ,  C07F9/572 ,  C07D417/06 ,  C07F7/08 ,  C07D401/14 ,  C07D403/14 ,  C07D403/12 ,  C07D209/42 ,  C07D471/08 ,  C07D209/30 ,  C07D209/44 ,  C07D209/88 ,  C07D209/12 ,  A61K31/519 ,  A61K31/501 ,  A61K9/00 ,  A61K31/4045 ,  A61K31/444 ,  A61K31/675 ,  A61K31/404 ,  A61K31/407 ,  A61K31/4162 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4188 ,  A61K31/4192 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/549 ,  A61K31/55 ,  C07F9/6558 ,  C07F9/6561 ,  C07D513/04 ,  C07B59/00 ,  C07D471/04 ,  C07D209/14 ,  C07D209/40 ,  C07D405/12 ,  C07D417/12 ,  C07D487/14 ,  C07D491/113 ,  C07D495/04 ,  C07D413/06 ,  C07D403/08 ,  C07D405/14 ,  C07D487/04 ,  C07D413/14 ,  C07D417/14 ,  C07D403/06 ,  C07F5/02

Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

公开(公告)号：US10323180B2

公开(公告)日：2019-06-18

申请号：US15532876

申请日：2015-12-03

Applicant: GUANGZHOU CHINARAY OPTOELECTRONIC MATERIALS LTD.

Inventor： Junyou Pan ,  Xiaolin Yan ,  Hong Huang

IPC: C07B59/00 ,  C09K11/06 ,  C07C255/58 ,  C07D221/20 ,  C07D403/10 ,  C07D403/14 ,  C07D487/04 ,  C07D487/16 ,  C07D519/00 ,  C07D209/86 ,  C07D209/88 ,  H01L51/00 ,  C07D413/10 ,  C07D209/08 ,  C07D209/10 ,  H01L51/50

Abstract: The present disclosure discloses a deuterated organic compound and a formulation and an organic electronic device containing the same, wherein the deuterated organic compound has the following structural formula: wherein Ar is an aromatic or heteroaromatic structural unit, D is an electron donor group, A is an electron acceptor group, n and m are an integer between 1 and 6; and wherein for the organic compound, (S1−T1)≤0.25 eV, and at least one H atom of the organic compound is substituted by deuterium. The present disclosure achieves the improvement of the electroluminescence quantum efficiency and the lifetime of the organic compound by replacing the H atom in the organic compound with deuterium and having (S1−T1)≤0.35 eV, and the material of the present disclosure has a great application potential and application range due to its low cost and relatively simple synthesis process.

公开(公告)号：US20190157568A1

公开(公告)日：2019-05-23

申请号：US16260111

申请日：2019-01-29

Applicant: Samsung Display Co., Ltd.

Inventor： Seok-Hwan HWANG ,  Young-Kook KIM ,  Yoon-Hyun KWAK ,  Jong-Hyuk LEE ,  Kwan-Hee LEE ,  Min-Seung CHUN

IPC: H01L51/00 ,  C09K11/06 ,  H01L27/32 ,  C07D209/88 ,  H01L51/52 ,  H05B33/14

CPC classification number: H01L51/0061 ,  C07D209/88 ,  C09K11/06 ,  C09K2211/1011 ,  C09K2211/1014 ,  C09K2211/1022 ,  C09K2211/1029 ,  C09K2211/185 ,  H01L27/3209 ,  H01L27/3211 ,  H01L27/3248 ,  H01L51/0052 ,  H01L51/0058 ,  H01L51/006 ,  H01L51/0072 ,  H01L51/5016 ,  H01L51/5056 ,  H01L51/5072 ,  H01L51/5088 ,  H01L51/5092 ,  H01L51/5096 ,  H01L51/5206 ,  H01L51/5218 ,  H01L51/5221 ,  H01L51/5234 ,  H01L2251/301 ,  H01L2251/308 ,  H01L2251/558 ,  H05B33/14 ,  Y10S428/917 ,  Y10T428/10 ,  Y10T428/31504

Abstract: An organic light emitting device including: a substrate; a first electrode; a second electrode; and an organic layer interposed between the first electrode and the second electrode and including an emission layer, wherein one of the first electrode and the second electrode is a reflective electrode and the other is a semitransparent or transparent electrode, and wherein the organic layer includes a layer having at least one of the compounds having at least one carbazole group, and a flat panel display device including the organic light emitting device. The organic light emitting device has low driving voltage, excellent current density, high brightness, excellent color purity, high efficiency, and long lifetime.

公开(公告)号：US20190135752A1

公开(公告)日：2019-05-09

申请号：US16037309

申请日：2018-07-17

Applicant: Arena Pharmaceuticals, Inc.

Inventor： Robert M. Jones ,  Daniel J. Buzard ,  Sangdon Han ,  Sun Hee Kim ,  Juerg Lehmann ,  Brett Ullman ,  Jeanne V. Moody ,  Xiuwen Zhu ,  Scott Stirn

IPC: C07D209/94 ,  A61K31/137 ,  C07D401/14 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/404 ,  C07C279/14 ,  C07C255/03 ,  C07C229/26 ,  C07C211/27 ,  C07D417/12 ,  C07D403/12 ,  C07D401/12 ,  C07D209/88 ,  C07D209/70 ,  A61K31/198

Abstract: The present invention relates to certain substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 receptor-associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, microbial infections or diseases and viral infections or diseases.